Assess whether RWE can replace or only supplement an RCT (09191f)

Situation

In a 505(b)(2) program relying on literature plus a bridging study, 505(b)(2) literature-to-product bridge table is the evidence after a CRL citing manufacturing, not efficacy. Labeling negotiator has to pick RWE can replace or Only supplement an RCT for this Pharma & Life Sciences CMC and Development Pathways close using 505(b)(2) literature-to-product bridge table.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose RWE can replace / Only supplement an RCT using 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• The population in 505(b)(2) literature-to-product bridge table is the one a CRL citing manufacturing, not efficacy named, so RWE can replace follows for this CMC and Development Pathways file.
• The population in 505(b)(2) literature-to-product bridge table is adjacent only to a CRL citing manufacturing, not efficacy; Only supplement an RCT is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained a CRL citing manufacturing, not efficacy before 505(b)(2) literature-to-product bridge table arrived; no new CMC and Development Pathways path.
• Provenance on 505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy is broken; do not pick RWE can replace or Only supplement an RCT yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a CRL citing manufacturing, not efficacy and write the one fact that would move RWE can replace or for labeling negotiator.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a CRL citing manufacturing, not efficacy). The follow-on CMC and Development Pathways action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.